natgillin/translations-raw huggingface dataset:
The coating composition according to any one of the preceding claims, wherein the binder system comprises a cross-linker selected from tetraethoxysilane; vinyltris(methylethyloximo)silane; methyltris(methylethyloximo)silane; vinyltrimethoxysilane; methyltrimethoxysilane and vinyltriisopropenoxysilane; and hydrolysis-condensation products of the same. 
Smjesa za premaz prema jednom od prethodno navedenih patentnih zahtjeva, naznačena time da sustav veziva sadrži sredstvo za poprečno povezivanje odabrano iz tetraetoksisilana; viniltrisćmetiletiloksimo)silana; metiltris(metiletiloksimo)silana; -viniltrimetoksisilana; "metiltrimetoksisilana i viniltriizopropenoksisilana; te njihovih proizvoda nastalih hidrolizom i kondenzacijom.
The diacid compounds of this invention are potent inhibitors of GST P1-1, and are also generally selective for GST P1-1 over GST A1-1 and GST M1-1, the two other human GST isoenzymes. 
Spojevi dikiselina ovog izuma su snažni inhibitori GST P1-1, 1 također su općenito selektivni za GST P1-1 preko GST Al-11GST MI1-1, druga dva humana GST izoenzima.
The second polypeptide typically facilitates secretion or expression of the first polypeptide. 
(33) Država ili organizacija podnošenja prve prijave: US 07.05.2008.
The resistance of the substrate beneath the PU top coat determines the flooring conductivity. 
Otpor podloge ispod gornjeg sloja od PU-a određuje vodljivost obloge.
is selected from hydrogen, cyano, cyclopropyl, difluoromethyl, halo, hydroxymethyl, methoxy, methyl, methylsulfonyl, trifluoromethoxy, trifluoromethyl, —CH2N(CH3)2, and a five-membered aromatic ring containing one, two, or three heteroatoms selected from nitrogen, oxygen, and sulfur; 
R? je odabrano od vodik, cijano, ciklopropil, difluorometil, halo, hidroksimetil, metoksi, metil, metilsulfonil, trifluorometoksi, trifluorometil, -CH2N(CH:),, i peteročlani aromatični prsten koji sadrži jedan, dva, ili tri heteroatoma odabrana od dušika, kisika, i sumpora;
The description of the production process according to the invention which is given below explains this with reference to a lateral arrangement structure of the groove structures 4 in the plate-shaped composite structure. 
Opis proizvodnog postupka prema izumu, koji se daje dolje, objašnjava to usporedbom s bočnom strukturom naprave od brazdastih struktura 4 u pločastoj kompozitnoj strukturi.
6 to 9). When the resiliency of the sealing member is procured by the geometrical shape, usually a deflection of the sealing member occurs (here: inwards and downwards deformation of the step). 
Kada se osigura elastičnost elementa za nepropusno zatvaranje geometrijskim oblikom, kao što je to definirano u patentnim zahtjevima, obično se javlja savijanje elementa za nepropusno zatvaranje (ovdje: deformacija stepenice prema unutra i prema dolje).
The engine (100) of claim 1, configured to add fuel either directly into the expansion cylinder (104) or to an exit end of the passage (144), timed to correspond with the valve opening. 
Motor (100) iz bilo kojeg patentnog zahtjeva od 1 do 9, naznačen time što je omjer volumena cilindra od DMT do GMT za ekspanzijski (104) cilindar ili za kompresijski (106) cilindar približno 80 prema | ili veći.
The compound or composition for use according to Claim 7, wherein the disease or condition is selected from the group consisting of either: 
Spoj ili pripravak za uporabu sukladno patentnom zahtjevu 7, naznačeno time što bolest ili stanje je odabrano iz skupine sastavljene od:
A method of separation of water/oil mixtures by filtering them through a hydrophilic material, different in the respect that the hydrophilic material is a-priori treated with an aqueous solution of polysaccharide microgels with a molecular mass of 20,000-200,000 Da and a particle size of 50-600 nm, and the concentration of microgels in the solution is 0.5-20 g/l. 
uvođenje u spomenutu vodu agensa koagulacije sastojeći se od vodene otopine polisaharidnih mikrogelova s molekularnom masom od 20.000 do 200.000 Da i veličinom čestice od 50 do 600 nm, spomenuta otopina imajući koncentraciju mikrogelova koja nije manja od 0.1g/l, tako da nakon tretmana spomenute lebdeće čestice nafte ili naftnih proizvoda bivaju premazane tankom polisaharidnom opnom;
A safety mechanism (401) as claimed in any preceding claim, wherein the receiver (360) is an acoustic receiver and the signal is an acoustic signal. 
Bunar (10) u skladu s bilo kojim prethodnim patentnim zahtjevom, naznačen time, da je prijemnik (360) ili primopredajnik (250, 360) akustički prijemnik ili primopredajnik (250,360) respektivno, a signal je zvučni signal.
The compound of claim 5, or a pharmaceutically acceptable salt thereof, wherein a is 0. 
Spoj ili sol za upotrebu prema zahtjevu 5, pri čemu a je 0.
The compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt thereof, wherein R8 is H, halo, CN, methyl, or Cy2; wherein Cy2 is selected from cyclopropyl, phenyl, a pyrazole ring, a pyridine ring, or a pyrimidine ring, each of which is optionally substituted by 1 R11 selected from OH, CN, fluoro, methyl, 2-hydroxyethyl, dimethylcarbamyl, amino, methylcarbamyl, and dimethylcarbamyl. 
Spoj iz bilo kojeg od patentnih zahtjeva od 1 do 12, ili njegova farmaceutski prihvatljiva sol, naznačen time, što R8 označava H, halogenu, CN, metil ili Cy2 grupu; i naznačen time, što je Cy2 izabrano iz grupe koju čine ciklopropil, fenil grupa, sistem prstena pirazola, sistem prstena piridina ili sistem prstena pirimidina, pri čemu svaka navedena grupa može biti supstituirana sa 1 R11 izabranim iz grupe koju čine OH, CN, fluoro, metil, 2-hidroksietil, dimetilkarbamil, amino, metilkarbamil i dimetilkarbamil grupa.
compressing the blend from the step (5) into a tablet; and 
komprimiranja smjese iz koraka (6) u tablete; i
An acid addition salt of a compound of the formula (1) 
Kombinacija koja sadrži kiselinsku adicijsku sol spoja formule (1) o
was treated with 56.9% aqueous hydriodic acid (22.5 ml.) 
tretira se sa 56,9% vodenom jodovodičnom kiselinom (22.5 ml.)
As shown in Figure 10, the juicer element 111 is secured to the bottom of the blender container 106 . 
Kako je prikazano na Slici 10, sokovnik 111 je pričvršćen za dno posude mješalice 106.
A method for selectively raising and lowering at least one structure to and from a predetermined position relative to a fixed support, comprising the steps of: providing a fixed support structure; 
Metoda selektivnog podizanja i spuštanja jedne ili više povišenih cijevi ili polica za kablove (12,112) do i od postavljenog položaja u odnosu na fiksnu potpornu strukturu (16,116), metoda sadržeći:
For determinations of antagonist IC50 values (concentrations of antagonist that inhibit responses to either pH 5.5 or capsaicin by 50%), at least 10 antagonist concentrations were measured in duplicate. 
Za utvrđivanje vrijednosti ICso antagonista (koncentracije antagonista koje inhibiraju reakcije na pH 5,5 ili na kapsacin za 50%), najmanje 10 koncentracija antagonista je izmjereno u duplikatu.
wherein said (methyl)Lanthionine bridge is of the size which comprises either two, three, four or five residues under the ring; or an amide, an ester or a salt thereof. 
(ili) pri čemu navedeni most (metiD)Lantionina je veličine koja sadrži dva, tri, četiri ili pet ostataka ispod prstena; ili njegov amid, ester ili sol.
If the answer is no, the adjusted dose AD is equal to the higher dose HD*, and the variable B is given the new value (B+DiffH) (step S 7). 
Metoda sukladno zaštiti 8, naznačena time što je prilagođena doza jednaka prvoj dozi ako je varijabla B negativna te je jednaka drugoj dozi ako je varijabla B pozitivna.
According to another preferred embodiment, both a portion of the excretion detector, the motion sensor, and the controller are located in a housing that is on the diaper. 
Postupak prema zahtjevu 1, kod kojeg u slučaju otkrivene izlučevine, modul pelene (2) emitira signal izlučivanja kako bi informirao korisnika.
The transdermal delievery device of item 21, further comprising an adhesive layer adjacent to, and in contact with, the matrix layer and permeable to the therapeutically active agent. 
Sredstvo za transdermalno davanje prema zahtjevu 14, naznačeno time da nadalje sadrži adhezivni sloj koji se nalazi pored i koji je u kontaktu s matričnim slojem i koji je propustan za terapeutski aktivni agens,
A deagglomerator according to claim 1 wherein the breath induced low pressure at the distal end of the airflow adaptor (100; 200; 300; 501; 601; 702) causes air to flow into the swirl chamber (414; 514) through the dry powder supply port (422; 522) and the inlet port (424; 425; 524; 525). 
703) koja ima proksimalni kraj i distalni kraj, adaptor protoka zraka (100; 200; 300; 501; 601; 702) dalje obuhvaća barem jednu drugu cijev (102-105; 204-206; 304-306; 502-505; 603-606) za omogućavanje strujanja zraka od proksimalnog kraja adaptora (100; 200; 300; 501; 601; 702) do distalnog kraja adaptora (100; 200;
Z represents any of the following substituents designated Z1 to Z7: wherein: 
Z predstavlja bilo koji od slijedećih supstituenata koji su označeni ZI do Z7:
The present invention therefore relates to oral pharmaceutical compositions containing an active ingredient having antimicrobial/anti-infectious activity, such as rifamicin SV and/or metronidazole, characterized in that they are formulated in such a manner as to release the active substances substantially in the portion of the large intestine where their specific sterilizing action is required, but leaving unaltered the non-pathogenic bacterial flora present in the portions of the small intestine which are not affected by the infection. 
<0,4 Ovaj izum se stoga odnosi na oralne farmaceutske pripravke koji sadrže aktivni sastojak antimikrobne/ antiinfektivno aktivnosti, kao što je rifamicin SV, karakterizirane time da su formulirani na način da se aktivni sastojak značajno otpušta u dijelu debelog crijeva gdje je potrebna specifična aktivnost sterilizacije, a da se pri tome nepatogena bakterijska flora prisutna u dijelovima tankog crijeva koje nije zahvaćeno infekcijom ostavi nepromijenjena.
Filtering the flow suctioned by the mobile suction means, with at least one filtration means; and 
filtriranje protoka usisanog mobilnim sredstvom za usisavanje (5), najmanje jednim sredstvom za filtriranje (3); i
What is meant by “deglycosylated or desialidated long pentraxin PTX3” is any PTX3, regardless of its natural (human or non-human) or recombinant origin. 
Dugi pentraksin PTX3 prema zahtjevu 1 ili 2, koji je prirodnog humanog ili nehumanog ili rekombinantnog porijekla.
The attenuated virus of item 1, wherein the virus is a poliovirus, rhinovirus, influenza virus, severe acute respiratory syndrome (SARS) coronavirus, Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), infectious bronchitis virus, Ebolavirus, Marburg virus, dengue fever virus, West Nile disease virus, Epstein-Barr virus (EBV), or yellow fever virus. 
Oslabljeni virus prema zahtjevu 1., naznačen time što je virus poliovirus, rinovirus, virus influence, teški akutni respiratorni sindrom (SARS), koronavirus, virus humane imunodeficijencije (HIV), virus hepatitisa € (HCV), virus infektivnog bronhitisa, virus Ebole, virus Marburg, virus denga groznice, virus groznice Zapadnog Nila, Epstein-Barr virus (EBV), ili virus žute groznice.
In one preferred aspect the outer layer comprises (a) Cocoa butter in an amount of 10 to 45 wt.% based on the outer layer, and (b) Shea butter in an amount of 55 to 80 wt.% based on the outer layer. 
(1) - vanjski sloj koji sadrži (a) tvrdi biljni maslac u količini od 10 do 45 mas. % bazirano na vanjskom sloju, i (b) mekani biljni maslac u količini od 55 do 80 mas. % bazirano na vanjskom sloju; i
As described herein, a number of clinical and prognostic breast cancer factors are known in the art and are used to predict treatment outcome and the likelihood of disease recurrence. Such factors include, for example, lymph node involvement, tumor size, histologic grade, estrogen and progesterone hormone receptor status, HER-2 levels, and tumor ploidy. 
Postupak u skladu s patentnim zahtjevom 6(1v), naznačen time što navedene kliničke varijable se bira iz skupine koju čine veličina tumora, status čvora, histološki stupanj, status receptora hormona estrogena, status receptora hormona progesterona, razine HER-2, te ploidnost tumora.
A recent review of ET-743, its chemistry, mechanism of action and preclinical and clinical development can be found in van Kesteren, Ch. et al., 2003, Anti - Cancer Drugs, 14 (7), pages 487-502: “Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin”, and references therein. 
Noviji prikaz ET-743, njegove kemije, mehanizma djelovanja i preklinički i klinički razvoj mogu se naći u van Kesteren, Ch. et at, 2003, Anti-Cancer Drugs, 14 (7), str. 487-502: "Vondelis (trabectedin, ET- 743): the development of an anticancer agent of marine origin", i referencama koje se u ovom radu navode.
A process for making a compound of formula (II), comprising the following step: wherein X, Y, Ra, PG1 and PG2 are as defined in claim 1. 
2. | Postupak za pripremu spoja formule (II), koji sadrži sljedeći korak: ePEa d ij Â«og
is hydrogen or C1-4-alkyl; n is 1 or 2; or a pharmaceutically acceptable acid addition salt, a racemic mixture, or its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. 
R> je vodik ili C,_,-alkil; nje lili 2; ili njegova farmaceutski prihvatljiva kiselinska adicijska sol, racemična smjesa, ili njegov odgovarajući enantiomer i/ili optički izomer i/ili stereoizomer.
treating the free acid produced in step (ii) with a tertiary amine in isopropylacetate to precipitate the tertiary amine salt of Formula Ic, 
(ili) obrada slobodne kiseline proizvedene u koraku (ii) s tercijarnim aminom u izopropilacetatu da se istaloži sol 20 tercijarnog amina Formule Ic,
reaction of L-aspartic acid, monomethyl ester A with 2-methyl propene to create compound B; 
(a) reakciju L-asparaginske kiseline, monometilni ester A s 2-metilpropenom, kako bi se dobio spoj B; s
is selected from the group consisting of CH and CR4 and X4 is NR8; or 
je odabran iz skupine koju čine CH2 i CHR4 i X4is NR8; ili
represents a leaving group under basic conditions in order to obtain the (4-pyridin-2-ylphenyl)acetic acid as an alkaline solution of the corresponding carboxylate salt. 
N pri čemu R* predstavlja grupu koja se otcjepljuje pod osnovnim uvjetima zbog izravnog dobivanja (4-piridin-2-ilfenil) octene kiseline koja se nadalje pročišćava.
Optionally, as shown in Figure 2A, the lighting end 11 of the fuel element may be tapered to improve lightability. 
Opcijski, kao što je prikazano na SI. 2A, kraj 11 za paljenje gorivog elementa 10 može biti ukošen za poboljšavanje paljenja.
The antibody or fragment according to claim 10 or 11, wherein the antibody is a fully human antibody, chimeric antibody, humanized or primatized antibody, and/or wherein the antibody is is selected from the group consisting of Fab, Fab', F(ab')2, F(ab'), F(ab), Fv or scFv fragment and minimal recognition unit. 
Protutijelo ili fragment protutijela prema zahtjevu 1 za uporabu u terapiji ili protutijelo ili fragment protutijela prema zahtjevu 2 za uporabu za liječenje raka, naznačeno time što je navedeno protutijelo ili fragment protutijela vezan na radioizotop, metalni kelator, fluorescentni spoj, bioluminiscentni spoj ili kemiluminiscentni spoj.
an inner non-effervescent material comprising at least a colouring and a solid carrier material, wherein the non-effervescent material is a free-flowing powder, wherein the non-effervescent material does not effervesce on contact with water; 
(i) unutarnji ne-pjenušavi materijal koji sadrži barem boju i kruti materijal nosača, pri čemu ne-pjenušavi materijal je prah koji slobodno teče, pri čemu se ne-pjenušavi materijal ne pjenuša u kontaktu s vodom;
The composition or vaccine of any one of claims 1-3 for use in a method of vaccinating an animal, said method comprising at least one administration of the composition or vaccine. 
Sastav ili cjepivo za uporabu prema bilo kojem od zahtjeva 1-8, naznačen/o time, da nadalje obuhvaća farmaceutski ili veterinarski prihvatljiv/o nosač, pomoćno sredstvo, prenositelj ili kemijski dodatak.
The method of claim 14 wherein said cardiovascular diseases are coronary heart disease, stroke, heart failure, systolic heart failure, diastolic heart failure, diabetic heart failure, heart failure with preserved ejection fraction, cardiomyopathy, myocardial infarction, left ventricular dysfunction, left ventricular dysfunction after myocardial infarction, cardiac hypertrophy, myocardial remodeling, myocardial remodeling after infarction or after cardiac surgery and valvular heart diseases. 
Spojevi ili kompozicija za primjenu u skladu sa patentnim zahtjevom 24 pri čemu spomenute kardiovaskularne bolesti su koronarna bolest srca, moždani udar, insuficijencija srca, sistolna insuficijencija srca, dijastolna insuficijencija srca, dijabetička insuficijencija srca, insuficijencija srca sa očuvanom ejektivnom frakcijom, kardiomiopatija, infarkt miokarda, lijeva ventrikularna disfunkcija, lijeva ventrikularna disfunkcija nakon infarkta miokarda, kardijalna hipertrofija, miokardijalno remodeliranje, miokardijalno remodeliranje nakon infarkta ili nakon operacije srca i valvularne bolesti srca.
Especially in summer periods consumption is high, while in colder periods consumption is low. 
Posebno u ljetnim periodima potrošnja je visoka, dok je u hladnim periodima potrošnja niska.
Use of E 78, wherein the dose of the IL-23 antagonist in the pharmaceutical composition is gradually reduced during the third treatment period. 
Uporaba u skladu sa zahtjevom 78, naznačena time, da se doza IL-23 antagonista u farmaceutskom pripravku postupno smanjuje tijekom trećeg razdoblja liječenja.
The extended release tablet formulation of claim 4, wherein the substantially neutral polymer is selected from hydroxypropylcellulose and hydroxypropylmethylcellulose. 
Formulacija tablete produljenog oslobađanja u skladu sa zahtjevom 4, naznačena time, da u biti neutralan polimer je izabran između hidroksipropilceluloze i hidroksipropilmetilceluloze.
The reaction mixture was then quenched with 1.5M HCl (750 ml) at this temperature and the product was extracted with MTBE (3×500 mL). 
Reakcija u reakcijskoj smjesi se potom pri toj temperaturi prekine s 1,5M HCI (750 mL), te se produkt ekstrahira pomoću MTBE (3x500 mL).
reacting the bacterial saccharide with 0.001-0.7 molar equivalents of periodate to form an activated bacterial saccharide; 
reakcija bakterijskog saharida s 0,001-0,7 molarnih ekvivalenata perjodata kako bi se dobio aktivirani bakterijski saharid;
X is a halogen atom, said compound of formula XXVII is further transformed and cyclized to generate a compound of formula XXVIII 
X je atom halogena; gdje se navedeni spoj formule XXVII daljnje pretvara i ciklizira kako bi se dobilo spoj formule XXVIII
represents hydrogen, bromine, or methoxy; 
R4 predstavlja vodik, brom ili metoksi;
Grout according to any one of the preceding claims, wherein the mineral filler is selected from: silica, alumina, quartz, calcite, bentonite, limestone, magnesite, gypsum, mica, talc, clays, coloured inerts, glasses, and mixtures thereof. 
Masa prema bilo kojem od prethodnih zahtjeva, gdje je mineralno punjenje izabrano od: silicija, glinice, kvarca, kalcita, bentonita, krečnjaka, magnezita, gipsa, liskuna, talka, gline, obojenih inertnih materijala, stakla, i njihove mješavine.
coupling a compound of formula 8: 
(a) spajanja spoja formule 8:
The compound of claim 1, selected from the following: or a pharmaceutically acceptable salt thereof. 
Spoj izabran od sljedećih spojeva, ili njegova farmaceutski prihvatljiva sol:
applying an electric current to the electrolytic cell sufficient to generate gaseous hydrogen and hydroxide ions at the cathode, wherein the metal chlorides dissociate to form metal ions and chloride ions, the metal ions reacting with the hydroxide ions to form metal hydroxides and the chloride ions passing through the anion exchange membrane, wherein the chloride ions undergo oxidation at the anode in the anode chamber to form gaseous chlorine, and wherein the gaseous chlorine and gaseous hydrogen are removed from the electrolytic cell and combined in a single pipeline by application of negative pressure; 
2. - primjenu električne struje na elektrolitičku ćeliju koja je dovoljna za stvaranje plinovitih vodikovih 1 hidroksidnih iona na katodi, pri čemu se metalni kloridi disociraju tako da tvore metalne ione i kloridne ione, te metalni ioni reagiraju s hidroksidnim ionima tako da tvore metalne hidrokside i kloridni ioni prolaze kroz anionsku izmjenjivačku membranu; pri čemu se kloridni ioni podvrgavaju oksidaciji na anodi u anodnoj komori da se dobije plinoviti klor; te pri čemu se plinoviti klor i plinoviti vodik miješaju dok se uklanjaju iz elektrolitičke ćelije i prikupljaju se primjenom negativnog tlaka;
A compound of formula (I) as claimed in claims 1 to 5 wherein R6 is hydroxy or C1-6 alkyl optionally substituted by piperidinyl, piperazinyl, morpholinyl, homomorpholinyl or homopiperazinyl. 
Spoj formule (I) prema zahtjevima 1 do 3, naznačen time da je R* hidroksi ili C,4 alkil opcionalno supstituiran piperidinilom, piperazinilom, morfolinilom, homomorfolinilom ili homopiperazinilom.
The compound according to claim 1 wherein n = 1 and R4 is OH or =O with the meaning of carbonyl. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što n = 1, a R4 je OH ili =O, sa značenjem karbonila.
The method of claim 4 wherein the pH is about 1 to about 4 pH units below the pI of the antibody. 
Postupak prema patentnom zahtjevu 4, naznačen time, da je pH otprilike 1 do otprilike 4 pH jedinice ispod pl protutijela.
Aspect 30. A mixture of at least two different Ig-like molecules obtainable by the methods according to any one of aspects 1-29. 
Smjesa najmanje dva različita antitijela koja se može dobiti pomoću postupaka u skladu s bilo kojim od patentnih zahtjeva 1-12.
A is a C3-C6cycloalkyl or a 4- to 10-membered heterocycloalkyl; wherein said cycloalkyl or heterocycloalkyl is optionally substituted with one to three substituents each independently selected from the group consisting of halogen and C1-C6alkyl; 
A je C3-C6cikloalkil ili 4- do 10-eročlani heterocikloalkil; gdje navedeni cikloalkil ili heterocikloalkil mogu biti supstituirani s jednim do tri supstituenta, od kojih se svaki neovisno bira iz skupine koju čine halogen i C1-C6alkil;
A cancer chemotherapeutic agent according to any of (1) to (4) above, which is in the form of a kit including a drug containing a cholestanol derivative and a drug containing an anti-cancer agent. 
Protutumorsko kemoterapijsko sredstvo u skladu s patentnim zahtjevom 1, naznačeno time, da je u obliku kompleta uključujući lijek koji sadrži derivat kolestanola 1 lijek koji sadrži protutumorsko sredstvo.
In some embodiments, compounds of the present invention are of Formula (Iv) wherein X is O (an oxygen atom). 
U nekim oblicima, spojevi prema izumu su Formule (Iv) gdje X je O (atom kisika).
The method of claim 15, wherein the second dose of fentanyl, or a pharmaceutically acceptable salt thereof, administered to the subject does not exceed 200 mcg of fentanyl or a pharmaceutically acceptable salt thereof. 
CNS 7056 ili njegova sol ili solvat za primjenu sukladno bilo kojem od zahtjeva 1 do 5 i 8, naznačen time što maksimalna doza fentanila po tretmanu ne prelazi 200 meg/pacijentu.
Process according to anyone of Claims 1 to 11, wherein the shaping step (iv) is carried out in a mould with at least one rounded shape, preferably a mould which has multiple tandemly arranged rounded shapes. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time, da se korak oblikovanja (iv) provodi u kalupu s najmanje jednim zaobljenim oblikom, poželjno kalupom koji ima višestruko zaobljene oblike raspoređene u paru.